Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 369-373

  Yun, S J ^a   Yoon, H Y ^a   Bae, S C ^a   Lee, O J ^a   Choi, Y H ^b   Moon, S K ^c   Kim, I Y ^d   Kim, W J ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Dong Eui University   (South Korea)

^c Chungju National University   (South Korea)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

prognostic markers; RUNX2; suppressor

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; NUCLEAR LOCALIZATION SIGNAL; ORGAN WEIGHT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RUNX2 GENE; STROMA CELL; TUMOR GENE;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CELL NUCLEOLUS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84869232324     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.31     Document Type: Article

References (18)

1. de Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function. Oncogene 2004; 23: 4238-4248. (Pubitemid 38758590)
2. Fukamachi H, Ito K. Growth regulation of gastric epithelial cells by Runx3. Oncogene 2004; 23: 4330-4335. (Pubitemid 38758598)
3. Tubert P, Rodriguez M, Ribo M, Benito A, Vilanova M. The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity. Invest New Drugs 2011; 29: 811-817.
4. Bradford WD, Dolan P. Getting used to it: the adaptive global utility model. J Health Econ 2010; 29: 811-820.
5. Boult C, Counsell SR, Leipzig RM, Berenson RA. The urgency of preparing primary care physicians to care for older people with chronic illnesses. Health Aff (Millwood) 2010; 29: 811-818.
6. Srivastava MC, Ramani GV, Garcia JP, Griffith BP, Uber PA, Park MH. Veno-venous extracorporeal membrane oxygenation bridging to pharmacotherapy in pulmonary arterial hypertensive crisis. J Heart Lung Transplant 2010; 29: 811-813.
7. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754. (Pubitemid 27516177)
8. Kobayashi H, Gao Y, Ueta C, Yamaguchi A, Komori T. Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 2000; 273: 630-636. (Pubitemid 30599036)
9. Stojanovic R, Todorovic Z, Vuckovic S, Nesic Z, Prostran M. Nitric oxide and lung diseases. Med Pregl 2003; 56(Suppl 1): 13-17.
10. Awiszus F. TMS and threshold hunting. Suppl Clin Neurophysiol 2003; 56: 13-23.
11. Clarke EJ, Allan VJ. Cytokeratin intermediate filament organisation and dynamics in the vegetal cortex of living Xenopus laevis oocytes and eggs. Cell Motil Cytoskeleton 2003; 56: 13-26. (Pubitemid 37059483)
12. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR et al. Rising prostate cancer rates in South Korea. Prostate 2006; 66: 1285-1291. (Pubitemid 44384305)
13. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010; 29: 811-821.
14. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runtdomain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003; 56: 13-22. (Pubitemid 36613151)
15. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006; 25: 589-600. (Pubitemid 46071865)
16. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005; 102: 1454-1459. (Pubitemid 40209191)
17. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002; 277: 2468-2476. (Pubitemid 34953269)
18. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009; 15: 4322-4335.